Literature DB >> 24453741

Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Stuart D Cook1, Suhayl Dhib-Jalbut1, Peter Dowling1, Luca Durelli1, Corey Ford1, Gavin Giovannoni1, June Halper1, Colleen Harris1, Joseph Herbert1, David Li1, John A Lincoln1, Robert Lisak1, Fred D Lublin1, Claudia F Lucchinetti1, Wayne Moore1, Robert T Naismith1, Carlos Oehninger1, Jack Simon1, Maria Pia Sormani1.   

Abstract

It has recently been suggested that the Lublin-Reingold clinical classification of multiple sclerosis (MS) be modified to include the use of magnetic resonance imaging (MRI). An international consensus conference sponsored by the Consortium of Multiple Sclerosis Centers (CMSC) was held from March 5 to 7, 2010, to review the available evidence on the need for such modification of the Lublin-Reingold criteria and whether the addition of MRI or other biomarkers might lead to a better understanding of MS pathophysiology and disease course over time. The conference participants concluded that evidence of new MRI gadolinium-enhancing (Gd+) T1-weighted lesions and unequivocally new or enlarging T2-weighted lesions (subclinical activity, subclinical relapses) should be added to the clinical classification of MS in distinguishing relapsing inflammatory from progressive forms of the disease. The consensus was that these changes to the classification system would provide more rigorous definitions and categorization of MS course, leading to better insights as to the evolution and treatment of MS.

Entities:  

Year:  2012        PMID: 24453741      PMCID: PMC3882992          DOI: 10.7224/1537-2073-14.3.105

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  109 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

Review 2.  Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?

Authors:  Douglas S Goodin
Journal:  Ann Neurol       Date:  2006-04       Impact factor: 10.422

3.  Contrast-enhanced MRI lesions during treatment with interferonbeta-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis.

Authors:  K Morgen; A L T Crawford; R D Stone; R Martin; N D Richert; J A Frank; H F McFarland
Journal:  Mult Scler       Date:  2005-04       Impact factor: 6.312

Review 4.  Magnetization transfer imaging to monitor the evolution of multiple sclerosis.

Authors:  M Filippi
Journal:  Ital J Neurol Sci       Date:  1999

5.  Defining interferon beta response status in multiple sclerosis patients.

Authors:  Richard A Rudick; Jar-Chi Lee; Jack Simon; Richard M Ransohoff; Elizabeth Fisher
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

6.  Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures.

Authors:  E M Mowry; A Beheshtian; E Waubant; D S Goodin; B A Cree; P Qualley; R Lincoln; M F George; R Gomez; S L Hauser; D T Okuda; D Pelletier
Journal:  Neurology       Date:  2009-05-19       Impact factor: 9.910

7.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Authors:  Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde
Journal:  Lancet Neurol       Date:  2009-02-07       Impact factor: 44.182

8.  Early MRI in optic neuritis: the risk for disability.

Authors:  J K Swanton; K T Fernando; C M Dalton; K A Miszkiel; D R Altmann; G T Plant; A J Thompson; D H Miller
Journal:  Neurology       Date:  2009-02-10       Impact factor: 9.910

9.  Multi-parametric MR assessment of T(1) black holes in multiple sclerosis : evidence that myelin loss is not greater in hypointense versus isointense T(1) lesions.

Authors:  I M Vavasour; D K B Li; C Laule; A L Traboulsee; G R W Moore; A L Mackay
Journal:  J Neurol       Date:  2007-11-12       Impact factor: 4.849

10.  Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.

Authors:  M Filippi; T Yousry; A Campi; C Kandziora; B Colombo; R Voltz; V Martinelli; S Spuler; S Bressi; G Scotti; G Comi
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

View more
  11 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

3.  Evolution of acute "black hole" lesions in patients with relapsing-remitting multiple sclerosis.

Authors:  Dejan Kostic; Evica Dincic; Aleksandar Jovanovski; Smiljana Kostic; Nemanja Rancic; Biljana Georgievski-Brkic; Miroslav Misovic; Katarina Koprivsek
Journal:  Acta Neurol Belg       Date:  2022-04-09       Impact factor: 2.396

4.  Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis.

Authors:  Samuel F Hunter; Jas Bindra; Ishveen Chopra; John Niewoehner; Mary P Panaccio; George J Wan
Journal:  Clinicoecon Outcomes Res       Date:  2021-10-11

5.  Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.

Authors:  Josa M Frischer; Stephen D Weigand; Yong Guo; Nilufer Kale; Joseph E Parisi; Istvan Pirko; Jay Mandrekar; Stephan Bramow; Imke Metz; Wolfgang Brück; Hans Lassmann; Claudia F Lucchinetti
Journal:  Ann Neurol       Date:  2015-08-24       Impact factor: 10.422

Review 6.  Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach.

Authors:  Tjalf Ziemssen; Raimar Kern; Katja Thomas
Journal:  BMC Neurol       Date:  2016-08-02       Impact factor: 2.474

Review 7.  Melanocortins, Melanocortin Receptors and Multiple Sclerosis.

Authors:  Robert P Lisak; Joyce A Benjamins
Journal:  Brain Sci       Date:  2017-08-14

Review 8.  Molecular biomarkers in multiple sclerosis.

Authors:  Tjalf Ziemssen; Katja Akgün; Wolfgang Brück
Journal:  J Neuroinflammation       Date:  2019-12-23       Impact factor: 8.322

9.  Long-term evolution of multiple sclerosis disability in the treatment era.

Authors:  Bruce A C Cree; Pierre-Antoine Gourraud; Jorge R Oksenberg; Carolyn Bevan; Elizabeth Crabtree-Hartman; Jeffrey M Gelfand; Douglas S Goodin; Jennifer Graves; Ari J Green; Ellen Mowry; Darin T Okuda; Daniel Pelletier; H-Christian von Büdingen; Scott S Zamvil; Alisha Agrawal; Stacy Caillier; Caroline Ciocca; Refujia Gomez; Rachel Kanner; Robin Lincoln; Antoine Lizee; Pamela Qualley; Adam Santaniello; Leena Suleiman; Monica Bucci; Valentina Panara; Nico Papinutto; William A Stern; Alyssa H Zhu; Gary R Cutter; Sergio Baranzini; Roland G Henry; Stephen L Hauser
Journal:  Ann Neurol       Date:  2016-08-13       Impact factor: 10.422

10.  Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials.

Authors:  A Traboulsee; Dkb Li; R Tam; G Zhao; A Riddehough; J Fang; F Dangond; L Kappos
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.